GEMCITABINE for Unresectable locally advanced pancreatic cancer|Pancreatic cancer

Inclusion criteria

• {"criterion_text":"- Able to comply with scheduled visits, treatment plan, able to undergo catheterization, imaging procedures, laboratory tests, required follow up visits, the filling out of required forms, and have the ability to understand and give written informed consent.\n- Have acceptable organ and marrow function as defined below: i.\tAbsolute neutrophil count (ANC) ≥ 1500 cells/mm³ (1.5x109 cells/L) ii.\tHemoglobin ≥ 9.0 g/dL iii.\tPlatelets ≥ 100,000/µL iv.\tTotal bilirubin ≤ 2 × upper limit of normal (ULN). v.\tAST (Aspartate Aminotransferase) ≤ 3 × ULN. vi.\tALT (Alanine Aminotransferase) ≤ 3 × ULN vii.\tCreatinine Within 1.5 x ULN OR Creatinine clearance ≥ 60 mL/min for patients with creatinine levels above 1.5 x ULN.\n- Women of childbearing potential (defined as all women who are not surgically sterile or postmenopausal for at least 1 year prior to enrollment) must have a negative urine pregnancy test at enrollment and must agree to use a medically acceptable contraception from enrollment until final treatment of Gemcitabine.\n- Male subjects who are planning to father a child (i.e., planning a pregnancy with a partner) during the clinical investigation. i.\tMale subjects must agree to use highly effective contraception with female partners of childbearing potential during the clinical investigation and for 3 months after the last dose of Gemcitabine and must not donate sperm during this period. ii.\tAcceptable methods include: combined hormonal contraception, progestogen-only contraception, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion in the female partner, or vasectomy of the male participant (confirmed azoospermia) plus an additional barrier method as required by local regulations. iii.\tSexual abstinence is acceptable only if it is the subject’s usual and preferred lifestyle; periodic abstinence and withdrawal are not acceptable.\n- Voluntarily agrees to participate and has duly singed the Informed Consent Form.\n- Age 18 years or older.\n- Histologically confirmed, locally advanced pancreatic cancer.\n- Systemic treatment with IV chemotherapy for at least six months.\n- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n- The target tumor is a measurable tumor according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria v1.1 prior to initiating Extroducer® Gemcitabine treatment.\n- Stable disease or locally progressive disease without signs of metastatic disease as evaluated at a multidisciplinary tumor board within 4 weeks prior to first dose.\n- Locally Advanced Pancreatic Cancer not amenable to resection as evaluated at a multidisciplinary tumor board within 4 weeks prior to first dose."}

Exclusion criteria

• {"criterion_text":"- Participating in another clinical investigation which may interfere with the results in this clinical investigation per investigator judgement.\n- Unmanaged concurrent illnesses, encompassing psychiatric conditions or challenging social circumstances, that, as per the investigator's judgment, could undermine compliance to the study protocols or pose an unacceptable risk to the patient.\n- Pregnant or nursing individuals.\n- Inability to consent.\n- Pancreatic tumor is different from adenocarcinoma (e.g., neuroendocrine, metastases). Adenosquamous is allowed.\n- Cancer has spread to other organs or non-regional lymph nodes (Metastases).\n- Unknown stage or recurrent pancreatic cancer.\n- Patient contraindication to Gemcitabine treatments.\n- Patients in which iodine contrast is contraindicated.\n- Presence of structures that impede tumor access.\n- Concurrent or prior malignancy unless disease-free for ≥3 years, with exceptions for nonmelanoma skin cancer, carcinoma in situ of the cervix or bladder, or Gleason Grade < 7 organ-confined prostate cancer. This may be subject to investigator’s judgement based on individual patient circumstances and the nature of the malignancy."}

Primary endpoints

• {"endpoint_text":"- Occurrence of Extroducer® related Serious Adverse Events within 72 hours post Extroducer® treatment infusion with Gemcitabine.","definition_or_measurement_approach":"Occurrence of Extroducer®-related Serious Adverse Events recorded within 72 hours after the Extroducer® treatment infusion with Gemcitabine (time-window specified: within 72 hours post infusion)."}

Secondary endpoints

• {"endpoint_text":"- Occurrence of Gemcitabine related Serious Adverse Events from first Extroducer® treatment infusion with Gemcitabine until study completion.","definition_or_measurement_approach":"Recording of Gemcitabine-related Serious Adverse Events from first infusion through study completion (time-to-event and incidence captured)."}
• {"endpoint_text":"- Survival rates (Overall Survival (OS) and Progression Free Survival (PFS)) at 6 months after final Extroducer® treatment infusion with Gemcitabine.","definition_or_measurement_approach":"Assessment of OS and PFS at 6 months after the final infusion (survival status and progression per imaging/clinical assessment)."}
• {"endpoint_text":"- Classification of tumor resectability according to NCCN resectability criteria before (baseline) and after (Visits 11-13) Extroducer® treatment infusion with Gemcitabine.","definition_or_measurement_approach":"Tumor resectability categorized per NCCN criteria at baseline and at Visits 11-13 post treatment."}
• {"endpoint_text":"- Classification of tumor response according to RECIST before (baseline) and after (Visits 11-13) Extroducer® treatment infusion with Gemcitabine.","definition_or_measurement_approach":"Tumor response assessed by RECIST v1.1 at baseline and at Visits 11-13."}
• {"endpoint_text":"- Evaluation of the tumor marker CA-19-9 before (baseline) and after (Visits 9, 11-13) Extroducer® treatment infusion with Gemcitabine.","definition_or_measurement_approach":"Measurement of CA 19-9 tumor marker at baseline and specified post-treatment visits (Visits 9, 11-13)."}
• {"endpoint_text":"- Evaluation of subjects’ quality of life using the EORTC QLQ-C30 and PANC26 questionnaires before (baseline) and after (Visits 11-13) Extroducer® treatment infusion with Gemcitabine.","definition_or_measurement_approach":"Quality of life assessed using EORTC QLQ-C30 and PANC26 questionnaires at baseline and Visits 11-13."}
• {"endpoint_text":"- The incidence, severity, and seriousness of Adverse Events and Device Deficiencies throughout the clinical investigation.","definition_or_measurement_approach":"Recording and categorization of adverse events and device deficiencies for incidence, severity, and seriousness across the study period."}

Sweden

Earliest CTIS Part Ii Submission Date

15-12-2025

Latest Decision Or Authorization Date

27-04-2026

Processing Time Days

133

Number Of Sites

1

Number Of Participants

9

Primary sponsor

Full Name

Smartwise Sweden AB

Organisation Type

Pharmaceutical company

Country Of Registered Address

Sweden